Wnt5a/Ca <sup>2+</sup> /calcineurin/nuclear factor of activated T signaling pathway as a potential marker of pediatric melanoma

Yang, Yi; Qiu, Qian

doi:10.4103/0973-1482.145788

Cited by 3 publications

(1 citation statement)

References 81 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…WNT5A promotes malignant progression in tumor cells [22–23] and is overexpressed in many types of cancer [22–24] (Table 4). RSPO2 inhibits tumor cell migration [49], implying it might also have therapeutic effects in FPA.…”

Section: Discussionmentioning

confidence: 99%

T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma

Zhong

et al. 2019

Aging

View full text Add to dashboard Cite

We tested whether the drugs T5224, RSPO2, and AZD5363 exert therapeutic effects against functioning pituitary adenoma (FPA). We analysed the gene expression profiles of four FPA mRNA microarray datasets (GSE2175, GSE26966, GSE36314, and GSE37153) from the Gene Expression Omnibus database and identified genes differentially expressed in FPA vs control tissues. We then carried out Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction network analyses. We also measured the difference in expression of hub genes between human normal pituitary cells and FPA cells using qRT-PCR. Our in vitro colony-formation and MTT assays showed that cell viability, number, and the size of clonogenicities were all lower in the presence of T5224, RSPO2, or AZD536 than in controls. Moreover, flow cytometry experiments showed that the incidence of apoptosis was higher in the presence of T5224, RSPO2, or AZD5363 than among controls, and was increased by increasing the doses of the drugs. This suggests these drugs could be used as therapeutic agents to treat FPA. Finally, we found that cFos, WNT5A, NCAM1, JUP, AKT3, and ADCY1 are abnormally expressed in FPA cells compared to controls, which highlights these genes as potential prognostic and/or therapeutic targets.

show abstract

Section: Discussionmentioning

confidence: 99%

T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma

Zhong

et al. 2019

Aging

View full text Add to dashboard Cite

show abstract

Retracted: MicroRNA‐21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin: An in vitro study

Zhang

Zeng

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

This study explored Cisplatin resistance effect of microRNA-21 (miR-21) antisense oligonucleotide (AS-ODN) in human melanoma A375 cell. AS-ODN was transfected in melanoma A375 cells and Cisplatin-resistant cell line A375/CDDP, and divided into the AS-ODN, nonsense oligonucleotide (NS-ODN) and normal groups. Cell ultrastructure changes were observed through transmission electron microscope. MiR-21 AS-ODN could be tested cell growth effect in different time periods by trypan blue exclusion. MiR-21 mRNA expression change was detected by quantitative fluorescence PCR. Cell apoptosis, cycle distribution and miR-21 AS-ODN effect on proliferation and Cisplatin sensitivity were tested by flow cytometry, MTT assay, TUNEL, and Clonogenic assay. Cell apoptosis was observed after transfection 24 h with the AS-ODN group, while the NS-ODN and normal group cells had no apoptotic symptoms; Compared with the normal group, the AS-ODN group began to show obvious cell growth inhibition effect after transfection 24 h lasting 72 h (all P < 0.05), but the NS-ODN group had no significant difference (P > 0.05). miR-21 mRNA expression in the AS-ODN group was obviously decreased with rising apoptosis rate (all P < 0.05) and there was no significant difference in the NS-ODN group (P > 0.05). MiR-21 AS-ODN could remarkably increase A375 cell and A375/CDDP cell sensitivity to Cisplatin (P < 0.05), while A375 cell sensitivity to Cisplatin between the NS-ODN group and the normal group had no difference. MiR-21 AS-ODN decreased IC and increased Cisplatin sensitivity for A375 cells and A375/CDDP cells, which would be a new target of melanoma treatment.

show abstract

Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the β-Catenin Pathway in the Hair Follicle Bulge Stem Cells

Goldstein

Koster

Jones

et al. 2018

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Vitiligo repigmentation is a complex process in which the melanocyte-depleted interfollicular epidermis is repopulated by melanocyte precursors from hair follicle bulge that proliferate, migrate, and differentiate into mature melanocytes on their way to the epidermis. The strongest stimulus for vitiligo repigmentation is narrow-band UVB (NBUVB), but how the hair follicle melanocyte precursors are activated by UV light has not been extensively studied. To better understand this process, we developed an application that combined laser capture microdissection and subsequent whole transcriptome RNA sequencing of hair follicle bulge melanocyte precursors and compared their gene signatures to that of regenerated mature epidermal melanocytes from NBUVB-treated vitiligo skin. Using this strategy, we found up-regulation of TNC, GJB6, and THBS1 in the hair follicle bulge melanocytes and of TYR in the epidermal melanocytes of the NBUVB-treated vitiligo skin. We validated these results by quantitative real-time-PCR using NBUVB-treated vitiligo skin and untreated normal skin. We also identified that GLI1, a candidate stem cell-associated gene, is significantly up-regulated in the melanocytes captured from NBUVB-treated vitiligo bulge compared with untreated vitiligo bulge. These signals are potential key players in the activation of bulge melanocyte precursors during vitiligo repigmentation.

show abstract

Wnt5a/Ca ²⁺ /calcineurin/nuclear factor of activated T signaling pathway as a potential marker of pediatric melanoma

Cited by 3 publications

References 81 publications

T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma

T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma

Retracted: MicroRNA‐21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin: An in vitro study

Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the β-Catenin Pathway in the Hair Follicle Bulge Stem Cells

Contact Info

Product

Resources

About

Wnt5a/Ca 2+ /calcineurin/nuclear factor of activated T signaling pathway as a potential marker of pediatric melanoma

Cited by 3 publications

References 81 publications

T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma

T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma

Retracted: MicroRNA‐21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin: An in vitro study

Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the β-Catenin Pathway in the Hair Follicle Bulge Stem Cells

Contact Info

Product

Resources

About

Wnt5a/Ca ²⁺ /calcineurin/nuclear factor of activated T signaling pathway as a potential marker of pediatric melanoma